BR9610848A - Imunidade contra apx de toxinas rtx de actinobacillus pleuropneumoniae - Google Patents

Imunidade contra apx de toxinas rtx de actinobacillus pleuropneumoniae

Info

Publication number
BR9610848A
BR9610848A BR9610848-7A BR9610848A BR9610848A BR 9610848 A BR9610848 A BR 9610848A BR 9610848 A BR9610848 A BR 9610848A BR 9610848 A BR9610848 A BR 9610848A
Authority
BR
Brazil
Prior art keywords
rtx
toxin
precursor
post
gene
Prior art date
Application number
BR9610848-7A
Other languages
English (en)
Inventor
Christopher Thomas Prideaux
Adrian Leslie Mark Hodgson
Original Assignee
Commw Scient Ind Res Org
Pig Res And Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3790639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9610848(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Commw Scient Ind Res Org, Pig Res And Dev Corp filed Critical Commw Scient Ind Res Org
Publication of BR9610848A publication Critical patent/BR9610848A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<B>IMUNIDADE CONTRA APX DE TOXINAS RTX DE ACTINOBACILLUS PLEUROPNEUMONIAE<D> A presente invenção fornece um microorganismo modificado que produz uma toxina RTX, em que a referida toxina RTX é parcial ou totalmente inativada. Em uma modalidade adicional da presente invenção, é fornecido um microorganismo modificado em que um gene de toxina RTX incluindo um gene estrutural RTX e/ou um ativador pós-translação do organismo é parcial ou totalmente inativado. Os presentes depositantes descobriram que um precursor de uma toxina RTX tem atividade tóxica reduzida. De forma surpreendente, o percursor de toxina RTX é capaz de induzir uma resposta imune em um animal que oferece proteção cruzada contra desafio heterólogo com um microorganismo que produz a toxina RTX. Um Microorganismo que produz naturalmente uma toxina RTX pode ser construído para produzir um precursor de toxina RTX inativo eliminando o ativador pós-translação do produto precursor. Por conseguinte, em uma modalidade preferida o microoganismo é incapaz de produzir um ativador pós-translação do precursor de toxina RTX ou produz um ativador pós-translação inativado do precursor do toxina RTX. O ativador pós-translação pode ser um produto do gene RTX C. Em um aspecto adicional a presente invenção fornece um vetor de plasmídeo recombinante para expressão de proteínas heterólogas em Actinobacillus ou organismos correlatos. Em uma modalidade preferida o vetor de plasmídeo recombinante é derivado de um plasmídeo de ocorrência natural em Actinobacillus pleuropneumoniae. O plasmídeo recombinante pode incluir uma sequência de DNA que codifica um precursor de toxina RTX. O plasmídeo recombinante pode incluir um gene RTX A. Alternativamente, o plasmídeo recombinante pode incluir um gene RTX C ou um seu fragmento.
BR9610848-7A 1995-11-02 1996-11-01 Imunidade contra apx de toxinas rtx de actinobacillus pleuropneumoniae BR9610848A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN6314A AUPN631495A0 (en) 1995-11-02 1995-11-02 Vaccine and biological vector(I)
PCT/AU1996/000686 WO1997016532A1 (en) 1995-11-02 1996-11-01 Immunity against actinobacillus pleuropneumoniae's rtx toxins apx

Publications (1)

Publication Number Publication Date
BR9610848A true BR9610848A (pt) 2001-10-09

Family

ID=3790639

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9610848-7A BR9610848A (pt) 1995-11-02 1996-11-01 Imunidade contra apx de toxinas rtx de actinobacillus pleuropneumoniae
BRPI9610848-7B8D BR9610848B8 (pt) 1995-11-02 1996-11-01 Actinobacillus pleuropneumoniae (app) transgênico, composição de vacina e vetor biológico transgênico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9610848-7B8D BR9610848B8 (pt) 1995-11-02 1996-11-01 Actinobacillus pleuropneumoniae (app) transgênico, composição de vacina e vetor biológico transgênico.

Country Status (12)

Country Link
US (1) US6472183B2 (pt)
EP (1) EP0861319B1 (pt)
JP (1) JP3905128B2 (pt)
KR (1) KR100448225B1 (pt)
AU (2) AUPN631495A0 (pt)
BR (2) BR9610848A (pt)
CA (1) CA2236699C (pt)
DE (1) DE69636040T2 (pt)
DK (1) DK0861319T3 (pt)
ES (1) ES2262159T3 (pt)
NZ (1) NZ320026A (pt)
WO (1) WO1997016532A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN631395A0 (en) * 1995-11-02 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Vaccine and biological vector(II)
HU226219B1 (en) * 1996-05-31 2008-06-30 Intervet Int Bv Live attenuated rtx-producing bacteria of the family pasteurellaceae
EP0875574A3 (en) * 1997-04-10 2000-03-22 Akzo Nobel N.V. Live attenuated bacteria of the species Actinobacillus pleuropneumoniae
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
ES2251268B1 (es) * 2002-07-15 2007-07-01 Universidad Del Pais Vasco Euskal Herriko Unibertsitatea Peptidos derivados de toxinas rtx para la proteccion de celulas del ataque por toxinas bacterianas.
ES2233145B1 (es) * 2002-11-20 2006-07-16 Laboratorios Hipra, S.A. Vacuna viva atenuada contra la pleuroneumonia porcina.
US20040209370A1 (en) * 2002-12-19 2004-10-21 Wonchul Suh Method for chromosomal engineering
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
ES2416154B1 (es) 2011-11-09 2015-04-01 Laboratorios Hipra, S.A. Cepa viva atenuada de Actinobacillus pleuropneumoniae
CN102517232B (zh) * 2011-12-15 2013-07-31 中国农业科学院哈尔滨兽医研究所 一种不含抗性标记的猪胸膜肺炎放线杆菌双基因缺失株、其构建方法及应用
US11149246B2 (en) * 2016-12-29 2021-10-19 Shoreline Biome, Llc Methods for cell lysis and preparation of high molecular weight DNA from modified cells
CN111511393A (zh) 2017-12-20 2020-08-07 英特维特国际股份有限公司 一种针对胸膜肺炎放线杆菌保护猪的疫苗
EP3689373A1 (en) 2019-01-30 2020-08-05 IDT Biologika GmbH Inactivated apxia, apxiia and apxiiia toxins
GB202011902D0 (en) 2020-07-30 2020-09-16 Imperial College Innovations Ltd Antinobacillus pleuropneumoniae vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641653A (en) * 1989-10-31 1997-06-24 The Texas A&M University System DNA encoding Actinobacillus pleuropneumoniae hemolysin
CA2085828A1 (en) 1991-12-23 1993-06-24 Agnes Ter Huurne Serpulina hyodysenteriae vaccine
CA2170839A1 (en) 1995-03-01 1996-09-02 Janet Macinnes Bacterial preparations, method for producing same, and their use as vaccines
EP0810283A3 (en) * 1996-05-31 1997-12-10 Akzo Nobel N.V. Live attenuated RTX-procucing bacteria of the family Pasteurellaceae
WO1998046260A1 (en) * 1997-04-15 1998-10-22 Baylor College Of Medicine Pasteurella haemolytica vaccine

Also Published As

Publication number Publication date
AUPN631495A0 (en) 1995-11-23
DE69636040D1 (de) 2006-05-24
US6472183B2 (en) 2002-10-29
KR100448225B1 (ko) 2005-06-17
BR9610848B8 (pt) 2014-08-05
NZ320026A (en) 1999-10-28
DE69636040T2 (de) 2006-12-07
US20020022035A1 (en) 2002-02-21
CA2236699A1 (en) 1997-05-09
DK0861319T3 (da) 2006-09-04
JP3905128B2 (ja) 2007-04-18
EP0861319A4 (en) 2001-10-10
KR19990067268A (ko) 1999-08-16
ES2262159T3 (es) 2006-11-16
JPH11514878A (ja) 1999-12-21
AU7268696A (en) 1997-05-22
EP0861319A1 (en) 1998-09-02
CA2236699C (en) 2009-08-11
EP0861319B1 (en) 2006-04-12
WO1997016532A1 (en) 1997-05-09
AU717769B2 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
Abdolmohammadi Khiav et al. Vaccination against pathogenic clostridia in animals: a review
PT826051E (pt) Derivados de toxina botulinica capazes de modificar funcoes aferentes sensoriaisperifericas
BR9610511B1 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
ATE228856T1 (de) Mittel für die steuerung von der zellaktivität
Richard et al. Bacterial toxins modifying the actin cytoskeleton
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
NO981353L (no) Regulerte gener og anvendelser derav
ATE314475T1 (de) Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
BRPI0413024A (pt) sistema de expressão de gene de inseto, promotor, vetor, inseto e, método para estabelecer compatibilidade de um promotor com uma espécie
EP1136561A3 (en) Targeting gene therapy
EP0657534A4 (en) ANTIALLERGIC AGING.
PT1204738E (pt) Processo para a diminuicao da formacao de espuma durante a cultura de um microrganismo
Boquet et al. Toxins from anaerobic bacteria: specificity and molecular mechanisms of action
Belyi et al. Bacterial toxin and effector glycosyltransferases
CA2236699A1 (en) Immunity against actinobacillus pleuropneumoniae&#39;s rtx toxins apx
BR9006855A (pt) Proteina de atividade urato oxidase,gene recombinante que a codifica,vetor de expressao,microorganismos e celulas transformadas
Wessels Cell wall and surface molecules: capsule
NO920162L (no) Hydrolysert vegetabilsk protein, samt fremgangsmaater for fremstilling av det
BRPI9600729A (pt) vetor de expressão, microorganismo transgênico, processo de clonagem de um ácido nucléico e processo para preparação de uma proteína e cepa de levedura transformada
BR9609102A (pt) Construção de dna recombinante e vetor útil para produzir transformantes de células de hospedeiro bacteriano
Wessels Cell wall and surface molecules of Streptococcus pyogenes: capsule
Ward Diphtheria toxin: a novel cytocidal enzyme
Vaishnavi Virulence factors associated with clostridiodes difficile: an overview
NO920163L (no) Hydrolysert vegetabilsk protein og fremstilling av et slikt
Stenmark et al. Interactions of diphtheria toxin B-fragment with cells. Role of amino-and carboxyl-terminal regions.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/11/2008, OBSERVADAS AS CONDICOES LEGAIS. COM RESSALVA NO QUE INCIDIR NO ART. 18 DA LEI 9.279/96.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE 14A. ANUIDADE(S).

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2107 DE 24/05/2011 E AO NAO RECOLHIMENTO DA 15A, 16A E 17A ANUIDADES.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061596/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132367-62.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: RAPIGENE, INC, WAKANAGA PHARMACEUTICAL CO., LTD, COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, PIG RESEARCH AND DEVELOPMENT CORPORATION, CONNAUGHT LABORATORIES LIMITED, ID BIOMEDICAL CORPOR

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061596/13 SECAO JUDICIARIA DO RIO DE JANEIRO - 13A VARA FEDERAL PROCESSO NO 2013.51.01.132367-3 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI REU(S): RAPIGENE INC., WAKUNAGA PHARMACEUTICAL CO.LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, PIG RESEARCH AND DEVELOPMENT CORPORATION, CONNAUGHT LABORATORIES LIMITED E ID BIOMEDICAL CORPORATION DECISAO: ANTE O EXPOSTO: A) JULGO EXTINTO O PROCESSO, SEM RESOLUCAO DE MERITO, COM BASE NO ART. 267, INCISO VI, DO CPC, PELA PERDA DO OBJETO, EM RELACAO AO PEDIDO FORMULADO EM FACE DE RAPIGENE INC., QUANTO A PATENTE PI9707056-4; B) JULGO PROCEDENTE A PRETENSAO DO INPI EM RELACAO A EMPRESA WAKUNAGA PHARMACEUTIC

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 1974 DE 04/11/2008, QUANTO AO PRAZO DE VALIDE POR DETERMINACAO DA 13A VARA FEDERAL DO RIO JANEIRO.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]